The clinical value of dual-time point 18F-FDG PET/CT for differentiating extrahepatic cholangiocarcinoma from benign disease

Clinical Nuclear Medicine

Volumn 38, Issue 3, 2013, Pages

  Choi, Eun Kyoung ^a   Yoo, Ie Ryung ^a   Kim, Sung Hoon ^a   Hyun O, Joo ^b   Choi, Woo Hee ^a   Na, Sae Jung ^c   Park, Sonya Youngju ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

delayed PET CT; dual time point PET CT; extrahepatic cholangiocarcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY STENT; BILIARY TRACT DRAINAGE; CANCER PATIENT; CANCER SCINTISCANNING; CHOLESTASIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AGED; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84874226360     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318266f402     Document Type: Article

References (35)

1. Okuda K, NakanumaY, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol. 2002;17:1049-1055.
2. Okuda K, Kubo Y, Okazaki N, et al. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer. 1977;39:232-246.
3. Callea F, Sergi C, Fabbretti G, et al. Precancerous lesions of the biliary tree. J Surg Oncol Suppl. 1993;3:131-133.
4. de Groen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N Engl J Med. 1999;341:1368-1378.
5. Lee WJ, Lim HK, Jang KM, et al. Radiologic spectrum of cholangiocarcinoma: emphasis on unusual manifestations and differential diagnoses. Radiographics. 2001;21(Spec No):S97-S116.
6. Nichols DA, MacCarty RL, Gaffey TA. Cholangiographic evaluation of bile duct carcinoma. AJR Am J Roentgenol. 1983;141:1291-1294.
7. Glasbrenner B, Ardan M, Boeck W, et al. Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography. Endoscopy. 1999;31:712-717.
8. Jailwala J, Fogel EL, Sherman S, et al. Triple-tissue sampling at ERCP in malignant biliary obstruction. Gastrointest Endosc. 2000;51:383-390.
9. Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc. 2002;56: 40-47.
10. Coleman RE. PET in lung cancer. J Nucl Med. 1999;40:814-820.
11. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2- deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 1997;203:795-800.
12. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PETwith the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1991;179:765-770.
13. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405-422.
14. Kluge R, Schmidt F, Caca K, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33:1029-1035.
15. Fritscher-Ravens A, Bohuslavizki KH, Broering DC, et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun. 2001;22: 1277-1285.
16. Reinhardt MJ, Strunk H, Gerhardt T, et al. Detection of Klatskin's tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patient studies. J Nucl Med. 2005;46:1158-1163.
17. Nishiyama Y, Yamamoto Y, Kimura N, et al. Comparison of early and delayed FDG PET for evaluation of biliary stricture. Nucl Med Commun. 2007;28: 914-919.
18. Kato T, Tsukamoto E, Kuge Y, et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging. 2002;29:1047-1054.
19. Petrowsky H, Wildbrett P, Husarik DB, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol. 2006;45:43-50.
20. KimJY, KimMH, Lee TY, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol. 2008;103:1145-1151.
21. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885-895.
22. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35:1308-1312.
23. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-1417.
24. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18- fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301-1306.
25. Choi BI, Lee JH, Han MC, et al. Hilar cholangiocarcinoma: comparative study with sonography and CT. Radiology. 1989;172:689-692.
26. Yamashita Y, Takahashi M, Kanazawa S, et al. Hilar cholangiocarcinoma. An evaluation of subtypes with CT and angiography. Acta Radiol. 1992;33: 351-355.
27. Robledo R, Muro A, Prieto ML. Extrahepatic bile duct carcinoma: US characteristics and accuracy in demonstration of tumors. Radiology. 1996;198:869-873.
28. Kumar V, Robbins SL. Robbins basic pathology. 8th ed. Philadelphia, PA: Saunders/Elsevier; 2007.
29. Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133: 510-515; discussion 515-516.
30. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18- fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
31. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35:1308-1312.
32. Laffon E, de Clermont H, Begueret H, et al. Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions. Nucl Med Commun. 2009;30: 455-461.
33. Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med. 2007;48:35-45.
34. Calder PC, Dimitriadis G, Newsholme P. Glucose metabolism in lymphoid and inflammatory cells and tissues. Curr Opin Clin Nutr Metab Care. 2007;10: 531-540.
35. Anderson CD, Rice MH, Pinson CW, et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8:90-97.